Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. Balcer LJ, Galetta SL, Polman CH, Eggenberger E, Calabresi PA, Zhang A, Scanlon JV, Hyde R J Neurol Sci. 2012 Apr 20. PMID: 22521274. Abstract CommentRecommendBookmarkWatch